Follicular lymphoma · 9 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bendamustine and Ofatumumab Variant #01 | — | R 1 183 675 | 28d | — | — | ~6 | ~R 3 259 566 indirect | — |
O-CHOP Variant #01 | — | R 667 072 | 21d | — | — | ~6 | ~R 2 721 606 indirect | — |
PCR Variant #03 Partial | — | R 103 769 | 28d | — | — | ~6 | ~R 208 140 indirect | — |
R-FCM Variant #01 | — | R 67 954 | 28d | — | — | ~6 | ~R 252 295 indirect | — |
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
R-CMD Variant #01 Partial | — | R 45 471 | 21d | — | — | ~4 | ~R 181 883 indirect | — |
Fludarabine and Rituximab (FR) Variant #01 | — | R 34 157 | 28d | — | — | ~6 | ~R 204 943 indirect | — |
VR-CHOP Variant #01 | — | R 30 327 | 21d | — | — | ~6 | ~R 181 963 indirect | — |
Ibritumomab tiuxetan protocol Variant #18 Partial | — | — | 8d | ~36.5 mo | — | ~1 | — | 1 |
9 of 9 regimens shown